JP2013525501A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525501A5
JP2013525501A5 JP2013509268A JP2013509268A JP2013525501A5 JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5 JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cyclodextrin
composition according
pazopanib
modified cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525501A (ja
JP5835717B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035363 external-priority patent/WO2011140343A1/en
Publication of JP2013525501A publication Critical patent/JP2013525501A/ja
Publication of JP2013525501A5 publication Critical patent/JP2013525501A5/ja
Application granted granted Critical
Publication of JP5835717B2 publication Critical patent/JP5835717B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509268A 2010-05-05 2011-05-05 医薬組成物およびその製造方法 Expired - Fee Related JP5835717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
US61/331,715 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (3)

Publication Number Publication Date
JP2013525501A JP2013525501A (ja) 2013-06-20
JP2013525501A5 true JP2013525501A5 (enExample) 2014-06-26
JP5835717B2 JP5835717B2 (ja) 2015-12-24

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509268A Expired - Fee Related JP5835717B2 (ja) 2010-05-05 2011-05-05 医薬組成物およびその製造方法

Country Status (26)

Country Link
US (3) US20110281901A1 (enExample)
EP (1) EP2566331B1 (enExample)
JP (1) JP5835717B2 (enExample)
KR (1) KR20130071434A (enExample)
CN (1) CN102970871A (enExample)
AR (1) AR081364A1 (enExample)
AU (1) AU2011247995B2 (enExample)
BR (1) BR112012028291A2 (enExample)
CA (1) CA2798386A1 (enExample)
CL (1) CL2012003075A1 (enExample)
CO (1) CO6640262A2 (enExample)
CR (1) CR20120556A (enExample)
DO (1) DOP2012000281A (enExample)
EA (1) EA201291168A1 (enExample)
ES (1) ES2519615T3 (enExample)
IL (1) IL222751A0 (enExample)
MA (1) MA34286B1 (enExample)
MX (1) MX2012012837A (enExample)
NZ (1) NZ603411A (enExample)
PE (1) PE20130217A1 (enExample)
PH (1) PH12012502159A1 (enExample)
SG (1) SG185087A1 (enExample)
TW (1) TW201206908A (enExample)
UY (1) UY33367A (enExample)
WO (1) WO2011140343A1 (enExample)
ZA (1) ZA201208265B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
HUE054113T2 (hu) 2010-08-05 2021-08-30 Forsight Vision4 Inc Injekciós készülék gyógyszerbejuttatáshoz
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
WO2013040247A2 (en) 2011-09-16 2013-03-21 Forsight Vision4, Inc. Fluid exchange apparatus and methods
RU2014137190A (ru) * 2012-02-17 2016-04-10 Фармасайкликс, Инк. Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
EP2824981B1 (en) * 2012-03-08 2019-02-27 Samsung Electronics Co., Ltd. Method for controlling service in radio communication system
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2978393B1 (en) 2013-03-28 2023-12-27 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
EP3039424B1 (en) 2013-08-28 2020-07-29 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
MY182793A (en) * 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
EP3238746B1 (en) 2014-12-25 2023-12-20 Kyoto University High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
KR20180133440A (ko) 2016-04-05 2018-12-14 포사이트 비젼4, 인크. 이식 가능한 안구 약물 전달 장치
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
WO2019028104A1 (en) * 2017-08-02 2019-02-07 Alphala Co., Ltd. NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP3810089B1 (en) * 2018-06-07 2023-08-02 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
KR20080071188A (ko) * 2005-11-29 2008-08-01 스미스클라인 비참 코포레이션 치료 방법
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CN101484136A (zh) * 2006-04-18 2009-07-15 Ekr治疗公司 预混合的、立即可用的药物组合物
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
ES2494365T3 (es) * 2008-01-30 2014-09-15 Genentech, Inc. Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso
WO2011009016A1 (en) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Similar Documents

Publication Publication Date Title
JP2013525501A5 (enExample)
JP5885670B2 (ja) 黄斑変性の処置のための組成物および方法
HRP20170021T1 (hr) Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol
PE20130217A1 (es) Composiciones farmaceuticas y metodos para su elaboracion
AR070824A1 (es) Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas
JP2011513492A5 (enExample)
CA2760140C (en) Topical solution formulations containing a corticosteroid and a cyclodextrin
JP2015527402A5 (enExample)
EA201370175A1 (ru) Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
AU2003230681A1 (en) Use of sulfoalkyl ether cyclodextrin as a preservative
JP2018021007A5 (enExample)
JP2013513612A5 (enExample)
RU2018117935A (ru) Водная композиция, содержащая дантролен
KR950016717A (ko) 제약 조성물
JP2016505044A5 (enExample)
HRP20140016T1 (hr) Suspenzije nanoäśestica koje sadrže karboksivinilni polimer
ES2548706T3 (es) Nanosuspensión farmacéutica
WO2010053487A1 (en) Composition containing sulfoalkyl ether cyclodextrin and latanoprost
KR102762379B1 (ko) 안과용 조성물
JP2023502914A (ja) ウルソデオキシコール酸の注射用組成物
JP5205909B2 (ja) 粘膜適用液剤
JP2018526420A5 (enExample)
TW201622700A (zh) 水性醫藥組成物
WO2014181368A8 (en) Aqueous ophthalmic formulations based on azithromycin
BR112020009719A2 (pt) composição aquosa